These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25676401)

  • 1. [Crizotinib treatment in a lung adenocarcinoma harboring ALK fusion gene with bone marrow metastasis: case report and literature review].
    Li X; Liu X; Gao F; Yin X
    Zhongguo Fei Ai Za Zhi; 2015 Feb; 18(2):85-8. PubMed ID: 25676401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Crizotinib Treatment Combined with Resection and Whole-brain Radiation Therapy 
in A ROS1 Rearranged Lung Adenocarcinoma with Brain Metastasis: 
Case Report and Literature Review].
    Zhang M; Nie L; Zhang J
    Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):525-9. PubMed ID: 27561802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
    Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
    Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
    Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
    J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
    Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
    Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma.
    Rosoux A; Pauwels P; Duplaquet F; D'Haene N; Weynand B; Delos M; Menon R; Heukamp LC; Thunnissen E; Ocak S
    Lung Cancer; 2016 Aug; 98():118-121. PubMed ID: 27393517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib.
    Shan L; Jiang P; Xu F; Zhang W; Guo L; Wu J; Zeng Y; Jiao Y; Ying J
    J Thorac Oncol; 2015 Jun; 10(6):e37-9. PubMed ID: 26001147
    [No Abstract]   [Full Text] [Related]  

  • 10. Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma.
    Caumont C; Veillon R; Gros A; Laharanne E; Bégueret H; Merlio JP
    Lung Cancer; 2016 Feb; 92():15-8. PubMed ID: 26775590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma.
    Tsukita Y; Fukuhara T; Kobayashi M; Morita M; Suzuki A; Watanabe K; Noguchi T; Kurata Y; Suno M; Maemondo M
    Intern Med; 2015; 54(24):3185-8. PubMed ID: 26666609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.
    Cui S; Zhao Y; Dong L; Gu A; Xiong L; Qian J; Zhang W; Niu Y; Pan F; Jiang L
    Cancer Med; 2016 Jun; 5(6):1013-21. PubMed ID: 26880708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
    Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
    Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central retinal artery occlusion, an early sign of crizotinib resistance in an alk positive adenocarcinoma of lung: A rare case report.
    Madabhavi I; Patel A; Anand A; Panchal H; Parikh S
    Clin Respir J; 2018 Feb; 12(2):806-810. PubMed ID: 27606884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian metastasis from lung adenocarcinoma with ALK-positive rearrangement detected by next generation sequencing: A case report and literatures review.
    Jing X; Li F; Meng X; Liu Z; Yu J; Liu B
    Cancer Biol Ther; 2017 May; 18(5):279-284. PubMed ID: 28362192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological Features and Therapeutic Responses of Chinese Patients with Advanced Lung Adenocarcinoma Harboring an Anaplastic Lymphoma Kinase Rearrangement.
    Lin D; Zeng D; Chen C; Wu X; Wang M; Chen J; Lin H; Qiu X
    Oncol Res Treat; 2017; 40(1-2):27-33. PubMed ID: 28118634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
    Ito K; Hataji O; Kobayashi H; Fujiwara A; Yoshida M; D'Alessandro-Gabazza CN; Itani H; Tanigawa M; Ikeda T; Fujiwara K; Fujimoto H; Kobayashi T; Gabazza EC; Taguchi O; Yamamoto N
    J Thorac Oncol; 2017 Feb; 12(2):390-396. PubMed ID: 27498387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report.
    Campos-Gomez S; Lara-Guerra H; Routbort MJ; Lu X; Simon GR
    Int J Biol Markers; 2015 May; 30(2):e254-7. PubMed ID: 25588859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement].
    Caliez J; Monnet I; Pujals A; Rousseau-Bussac G; Jabot L; Boudjemaa A; Leroy K; Chouaid C
    Rev Mal Respir; 2017 May; 34(5):576-580. PubMed ID: 27646667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.